Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Exelixis (EXEL) Stock Price & Analysis
2,763 Followers
EXEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.64 - $24.34
Previous Close$22.6
Volume1.35M
Average Volume (3M)1.80M
Market Cap
$6.58B
Enterprise Value$5.78B
Total Cash (Recent Filing)$995.30M
Total Debt (Recent Filing)$189.94M
Price to Earnings (P/E)35.0
Beta0.50
Next Earnings
Jul 31, 2024EPS Estimate
$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding291,292,704
10 Day Avg. Volume1,765,760
30 Day Avg. Volume1,799,912
Standard Deviation0.11
R-Squared0.08
Alpha0.00022
Financial Highlights & Ratios
Price to Book (P/B)2.94
Price to Sales (P/S)13.48
Price to Cash Flow (P/CF)152.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda22.05
Forecast
1Y Price Target
$26.71Price Target Upside18.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Exelixis News
PremiumCompany Announcements
Exelixis Shareholders Vote on Governance and Incentives
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement reiterated its previously issued 2024 guidance, which includes total revenues of $1.825-1.925B and net product revenues between $1.65-1.75B.
Pipeline And Growth PotentialExelixis' most advanced pipeline asset, zanzalintinib, is in three pivotal trials and has the potential to generate substantial revenue for the company.
Settlements And Patent ProtectionExelixis struck another win by reaching a settlement agreement with Cipla.
Bears Say
EarningsExelixis recorded diluted net income of $0.12 per share vs. previously forecast diluted net income of $0.33 per share; the difference can mainly be attributed to a lower than-forecast revenue and a higher than forecast operating expense.
Market CompetitionCABOMETYX nears loss of exclusivity for renal cell carcinoma in a highly competitive and saturated market, under risk of ANDA litigation that may shorten exclusivity.
Revenue PerformanceRevenues for cabozantinib (cabo) at $378.5mn, missing consensus by ~13%.
---
Ownership Overview
4.31% Insiders
29.16% Mutual Funds
27.20% Other Institutional Investors
39.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $18.64 and its highest was $24.34 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Apr 30, 2024. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.227 by -$0.107.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.31.
How many shares outstanding does Exelixis have?
Exelixis has 291,292,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.12 in its last earnings report, missing expectations of $0.227. Following the earnings report the stock price went down -6.564%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 633M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.71 (18.19% Upside)
$26.71 (18.19% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 198.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.66%
12-Months-Change
Fundamentals
Return on Equity
8.76%
Trailing 12-Months
Asset Growth
-10.80%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q1 2024
0:00 / 0:00
---
EXEL Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EXEL Stock 12 Month Forecast
Average Price Target
$26.71
▲(18.19% Upside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+103.45%
reiterated a buy rating 10 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +103.45% per trade.
---